Genetically engineered mosquitoes are due to be released in Burkina Faso, Mali and Uganda by the Target Malaria research consortium. Target Malaria is a consortium of research institutes that receives core funding from the Bill & Melinda Gates Foundation, Silicon Valley companies and the Pentagon. In Burkina researchers recently secured government approval to release up to 10,000 sterile male Anopheles gambiae mosquitoes.
Irene Teis's blog
May I share this document from the Belgian Journal NEOSANTE describing the impact of the movie displayed on French and Belgian channels.
Vehement critics of the wrongdoings of Bill Gates and Bigpharma who do the outmost they can not to eradicale malaria and keep this cash cow alive.
mercredi 29 novembre 2017
UNE VERITE ECLATE CE SOIR
Thank you MP for your blog http://mosquitopundit.net/mosquitopundit-blog/act-and-malaria-recrudesce....
You give me a lot of credit when you state: malaria researcher Irene Teis doesn’t know that her 2 April 2016 post “Was the Nobel prize for artemisinin a fatal error” at www.malariaworld.org helped save at least nine lives.
In 2015 a Nobel Price was attributed to Youyou Tu, almost 50 years after a report describing artemisinin’s structure, pharmacology, and efficacy had been published in 1979 by the “Qinghaosu Anti-Malarial Coordinating Research Group,” where she was a member of. Mr Huang Shuze, Deputy Minister of Health, stated in his 1981 summary report “Project 523 mobilized multiple departments ; thirty scientific research units and medical schools in 1975”.
The paper « Efficacy of a Novel Sublingual Spray Formulation of Artemether in African Children with Plasmodium falciparum Malaria » (Daryl Bendel et al.,Antimicrob. Agents Chemother. November 2015 vol. 59 no. 11 6930-6938) which was posted recently on www,malariaworld.org raises this important question. The clinical trials were run by an Australian pharmaceutical company in Burkina Faso, Rwanda and Ghana
The competitive product Artequick which the Chinese launched against Coartem and Coarsucam is now confronted by resistance like any other monotherapy. A letter to the editor by DL Saunders et al., in NEJM July 2014 describes the dihydroartemisinin-piperaquine failure in Cambodia. The drug was adopted as first line treatment in this country in 2010. Three years later the efficacy has decreased from 92% to 64%. At 72 hours 56% of patients still had persistent parasitemia.
A document in Scientific American (June 2014) describes the activities of MVV Medecines for Malaria Ventures, a « non profit » organization (association sans but lucratif) located at Geneva. It is surprising to learn that they sell Artesunate in monotherapy for intravenous injection at high doses ; in cooperation with WHO and Médecins sans Frontières.
This PhD thesis of A Sanner, Université de Nancy 1, clearly describes why Artemisia annua tea has no chance against the business of ACT pills and why WHO issued a veto on clinical trials with the herb. Full text on http://docnum.univ-lorraine.fr/public/SCDMED_T_2008_SANNER_ALEXANDRE.pdf
Haemolytic, hepatotoxic, cytotoxic, neurotoxic, cardiotoxic, genotoxic, ototoxic, embryotoxic, spleenotoxic, hemolytic, atherosclerosis, immunodepressive effects of chemical artemisinine derivatives (ACTs) at high doses.
Some recent research, mostly in relation with the resistance to ACT pills and/or artesunate injections, has highlighted serious secundary health effects at the doses prescribed by WHO.
WE are astonished that only 50 of the 7917 malaria experts on www.malariaworld.org have an opinion on synthetic artemisinin production and the impact this may have on farmers in poor countries. Somebody sent us yesterday the blog “Why Synthetic Artemisinin Is Still a Bad Idea “ from Jim Thomas of the ETC Group. Hereafter a few excerpts which deserve consideration